Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS
Status:
WITHDRAWN
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the cognitive benefits of ozanimod in individuals with Multiple Sclerosis (MS). The study aims to understand the neural basis of cognitive improvement in Relapsing-Remitting MS patients under ozanimod treatment using neuroimaging and behavioral techniques to characterize the brain and behavioral changes due to ozanimod treatment.